Pfizer supports the EFPIA submission to this call for feedback and appreciates the opportunity to elaborate further on some key areas. Pfizer shares the European Commissions goals to deliver faster, more equitable access to affordable medicines and mitigate shortages. We are driven by the understanding that patients cant afford any delays or disruptions in getting the medicines and vaccines they need.
PFI
Pfizer
Company · United States · EU Transparency Register 4263301811-33
5
positions filed
in the 665 files tracked
4
legislative files
of 665 tracked
3
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 665 consultation files tracked so far (57,774 submissions, mostly 2021–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 1210 companies & groups on this site, they rank #367 by legislative files engaged, a count of participation, not a measure of influence.
1.5
declared lobbying FTE
self-declared
€1.3M+
declared costs / yr (floor)
2
EP accreditations
as declared to the register
2008
in the register since
Declares membership of
- In 2025 Pfizer was a member of: EFPIA
- Vaccines Europe
- EuropaBio →
- Amcham EU
- BusinessEurope →
- European Policy Centre
- European Business Summits
- Friends of Europe.
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026).
- Register category
- Companies & groups
- Registered as
- Pfizer Inc. (PFE)
- Head office
- New York, United states
- EU office
- Brussels
Self-declared to the EU Transparency Register (snapshot 14 Oct 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Pfizer in PolicySpeak: request access →
Work at Pfizer? so we know who speaks for it.
Their record over time
Pfizer filed 5 positions between 4 Jan 2021 and 11 Jun 2025, across 4 of the 665 legislative files tracked here, attaching a full position paper 3 times.
2021 · 2 filed2023 · 2 filed2025 · 1 filed
What they argued
Pfizer acknowledges that access, affordability and availability of medicines are key priorities of the EU Pharma Strategy. We remain committed to partner with EU policy-makers to address these challenges. However, the root causes of obstacles to the availability of innovative medicines are multi-factorial and fall mostly beyond EU competences.
The upcoming Biotech Act offers an opportunity to enhance Europes position as a global leader in biotechnology. To remain at the forefront of scientific breakthroughs, the EU must adopt policies that address the challenges and leverage the opportunities in the biotech space.
As an innovative biopharmaceutical company, Pfizer is a global leader in R&D of new treatments for paediatric and rare diseases. In the EU, the framework created by the Orphan and Paediatric Medicines Regulations has allowed investment in areas of unmet need, to the benefit of millions of patients.
Pfizer welcomes the opportunity to respond to the proposal. Our purpose Breakthroughs that change patients lives fuels everything we do and reflects our passion for science and our commitment to patients. Alongside this, a strong system of intellectual property (IP) protection provides the economic incentive necessary to achieve sustainable scientific advancement and enable companies like Pfizer to apply their…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Pfizer next to another organization. Same files, same register facts, side by side. Compare →
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers, not evidence of coordination, and we do not suggest any.
Showing 5 of 103.
Is this your organization?
Everything on this page comes from Pfizer’s own submissions to the European Commission. We have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.